<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Terapevticheskii arkhiv</journal-id><journal-title-group><journal-title xml:lang="en">Terapevticheskii arkhiv</journal-title><trans-title-group xml:lang="ru"><trans-title>Терапевтический архив</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0040-3660</issn><issn publication-format="electronic">2309-5342</issn><publisher><publisher-name xml:lang="en">LLC Obyedinennaya Redaktsiya</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">32774</article-id><article-id pub-id-type="doi">10.26442/terarkh201890751-56</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Editorial article</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Передовая статья</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Immunoglobulinopathies in patients with angioimmunoblastic T-cell lymphoma</article-title><trans-title-group xml:lang="ru"><trans-title>Иммуноглобулинопатии у больных ангиоиммунобластной Т-клеточной лимфомой</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>CHERNOVA</surname><given-names>N G</given-names></name><name xml:lang="ru"><surname>ЧЕРНОВА</surname><given-names>Наталья Геннадьевна</given-names></name></name-alternatives><bio xml:lang="ru"><p>к.м.н., врач-гематолог отд-ния интенсивной высокодозной химиотерапии лимфом с круглосуточным и дневным стационаром, тел.: 8(495)612-48-10 (раб.), 8(916)660-27-63 (моб.); http://orcid.org/0000-0002-0827-4052</p></bio><email>ngchernova@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>SOBOLEVA</surname><given-names>N P</given-names></name><name xml:lang="ru"><surname>СОБОЛЕВА</surname><given-names>Наталья Павловна</given-names></name></name-alternatives><bio xml:lang="ru"><p>врач централизованной клинико-диагностической лаборатории, http://orcid.org/0000-0002-1903-2446</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>MARIINA</surname><given-names>S A</given-names></name><name xml:lang="ru"><surname>МАРЬИНА</surname><given-names>Салия Ахсановна</given-names></name></name-alternatives><bio xml:lang="ru"><p>врач централизованной клинико-диагностической лаборатории, http://orcid.org/0000-0002-9375-4076</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>SIDOROVA</surname><given-names>Y V</given-names></name><name xml:lang="ru"><surname>СИДОРОВА</surname><given-names>Юлия Владимировна</given-names></name></name-alternatives><bio xml:lang="ru"><p>к.м.н., с.н.с., http://orcid.org/0000-0003-1936-0084</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>SINITSYNA</surname><given-names>M N</given-names></name><name xml:lang="ru"><surname>СИНИЦЫНА</surname><given-names>Марина Николаевна</given-names></name></name-alternatives><bio xml:lang="ru"><p>н.с., http://orcid.org/0000-0002-0750-8005</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>DVIRNYK</surname><given-names>V N</given-names></name><name xml:lang="ru"><surname>ДВИРНЫК</surname><given-names>Валентина Николаевна</given-names></name></name-alternatives><bio xml:lang="ru"><p>к.м.н., зав. централизованной клинико-диагностической лабораторией, http://orcid.org/0000-0002-9877-0796</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>BADMAZHAPOVA</surname><given-names>D S</given-names></name><name xml:lang="ru"><surname>БАДМАЖАПОВА</surname><given-names>Дарима Сэмункоевна</given-names></name></name-alternatives><bio xml:lang="ru"><p>аспирант, https://orcid.org/ 0000-0002-4223-2366</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>VINOGRADOVA</surname><given-names>Y E</given-names></name><name xml:lang="ru"><surname>ВИНОГРАДОВА</surname><given-names>Юлия Ейхеновна</given-names></name></name-alternatives><bio xml:lang="ru"><p>к.м.н., доцент каф. госпитальной терапии №2, https://orcid.org/0000-0003-3353-1230</p></bio><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>ZVONKOV</surname><given-names>E E</given-names></name><name xml:lang="ru"><surname>ЗВОНКОВ</surname><given-names>Евгений Евгеньевич</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.м.н., зав. отд-нием интенсивной высокодозной химиотерапии лимфом с круглосуточным и дневным стационаром, http://orcid.org/0000-0002-2639-7419</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>SAVCHENKO</surname><given-names>V G</given-names></name><name xml:lang="ru"><surname>САВЧЕНКО</surname><given-names>Валерий Григорьевич</given-names></name></name-alternatives><bio xml:lang="ru"><p>акад. РАН, проф., генеральный директор, https://orcid.org/0000-0001-8188-5557</p></bio><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">National Research Center for Hematology Russian Federation</institution></aff><aff><institution xml:lang="ru">ФГБУ «Национальный медицинский исследовательский центр гематологии» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">The State Education Institution of Higher Professional Training The First Sechenov Moscow State Medical University under Ministry of Health of the Russian Federation</institution></aff><aff><institution xml:lang="ru">ГБОУ ВПО «Первый МГМУ им. И.М. Сеченова» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2018-07-15" publication-format="electronic"><day>15</day><month>07</month><year>2018</year></pub-date><volume>90</volume><issue>7</issue><issue-title xml:lang="en">VOL 90, NO7 (2018)</issue-title><issue-title xml:lang="ru">ТОМ 90, №7 (2018)</issue-title><fpage>51</fpage><lpage>56</lpage><history><date date-type="received" iso-8601-date="2020-04-11"><day>11</day><month>04</month><year>2020</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2018, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2018, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2018</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://ter-arkhiv.ru/0040-3660/article/view/32774">https://ter-arkhiv.ru/0040-3660/article/view/32774</self-uri><abstract xml:lang="en"><p>Contex. Angioimmunoblastic T-cell lymphoma (AITL) is a rare form of non-Hodgkins lymphoma, characterized by generalized lymphadenopathy, hepatosplenomegaly and dysproteinemia. Hypergammaglobulinaemia is revealed in 50-83% pts with AITL. However, the characteristics of immunoglobulinopathies observed in AITL are scarce. Objective: The aim of the study was to characterize quantitative and qualitative immunoglobulinopathies in patients with AITL at the onset of the disease. Patients and methods. 55 patients with newly diagnosed AITL were enrolled in the study, the male/female ratio was 30/25; median age was 61 (29-81) years. Diagnosis was based on standard WHO criteria. Immunochemical studies of blood serum included serum protein electrophoresis/immunofixation, nephelometric quantification of total immunoglobulins, serum free light chain assay. Results. Quantitative and qualitative immunoglobulinopathies were determined in 49 (89,1%) of 55 pts. Quantitative immunoglobulinopathies were revealed in 47 (85.5%) of 55 cases, qualitative - in 14 (25,5%). Combination quantitative and qualitative immunoglobulinopathies was observed in 12 (21,8%) of 55 pts. The detected immunoglobulinopathies were divided into 4 groups: polyclonal hypergammaglobulinaemia, hypogammaglobulinaemia, oligoclonal gammapathy, and monoclonal gammapathy. Polyclonal hypergammaglobulinaemia was marked in 41 (74.5%) of 55 pts, elevated level of IgG was determined in 27 (49,15%) of 55 cases, IgM - in 18 (32,7%) and IgA - in 21 (38.2%). Interestingly, polyclonal IgE hypergammaglobulinaemia was detected in 12 (48,0%) of 25 cases of performed studies. Hypogammaglobulinaemia was detected in 8 (14,5%) of 55 cases. Oligoclonal gammapathy was determined in 4 (7.3%) of 55 pts. Monoclonal gammapathy was revealed in 11 (20,0%) of 55 cases. The amount of monoclonal immunoglobulin varied from 2.6 to 14.1 g/l. Monoclonal immunoglobulin Gk was detected in 5 of 11 pts, Gλ - in 2, Mλ - in 2, Mk - in 2. Monoclonal gammapathy was accompanied by polyclonal hypergammaglobulinaemia in 9 of 11 cases, hypogammaglobulinaemia - in 2. Conclusions. Quantitative and qualitative immunoglobulinopathies are observed in most patients at the onset of AITL. Quantitative abnormalities were determined more often than qualitative. Monoclonal gammapathy can be a manifestation of lymphoproliferation and other concomitant disorders. The prognostic value of immunochemical parameters is still unclear and requires dynamic observation and study.</p></abstract><trans-abstract xml:lang="ru"><p>Цель. Охарактеризовать частоту выявления и типы иммуноглобулинопатий у первичных больных ангиоиммунобластной Т-клеточной лимфомой (АИТЛ). Материалы и методы. В исследование включено 55 первичных больных АИТЛ с медианой возраста 61 (29-81) год, соотношение мужчины/женщины - 30/25. Результаты. Исследование иммунохимических показателей продемонстрировало наличие иммуноглобулинопатий у 89,1% больных в дебюте АИТЛ. Поликлональная гипергаммаглобулинемия наблюдалась у 74,5% больных, в том числе класса G - в 49,2%, класса Е - в 48,0%, класса А - в 38,2%, класса М - в 32,7% случаев. Олигоклональная секреция выявлена у 7,3% больных, моноклональная секреция - у 20%. Гипогаммаглобулинемию наблюдали у 8 больных, в 2 случаях на фоне моноклональной секреции. Заключение. Количественные и качественные изменения иммуноглобулинов наблюдаются у большинства больных АИТЛ. Иммунохимическое исследование белков сыворотки крови является необходимым методом первичной диагностики этого вида лимфомы. Выявленная моноклональная секреция возможно является как проявление лимфопролиферации, так и сопутствующей моноклональной гаммапатии неопределенного значения. Прогностическое значение иммунохимических показателей на настоящий момент остается неясным и требует динамического наблюдения и изучения.</p></trans-abstract><kwd-group xml:lang="en"><kwd>angioimmunoblastic T-cell lymphoma</kwd><kwd>immunoglobulinopathies</kwd><kwd>polyclonal hypergammaglobulinaemia</kwd><kwd>hypogammaglobulinaemia</kwd><kwd>oligoclonal gammapathy</kwd><kwd>monoclonal gammapathy</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>ангиоиммунобластная Т-клеточная лимфома</kwd><kwd>иммуноглобулинопатии</kwd><kwd>поликлональная гипергаммаглобулинемия</kwd><kwd>гипогаммаглобулинопатия</kwd><kwd>олигоклональная секреция</kwd><kwd>моноклональная секреция</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Swerdlow S.H, Campo E, Harris N.L, Jaffe E.S, Pileri S.A, Stein H, Thiele J, Arber D.A, Hasserjian R.P, Le Beau M.M, Orazi A, Siebert R. WHO classification of tumors of haematopoietic and lymphoid tissues. Lyon: IARC, 2017: 407-12.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008 (1); 26(25):4124-30. doi:10.1200/ JCO.2008.16.4558</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Виноградова Ю.Е., Луценко И.Н., Кременецкая А.М., Капланская И.Б., Самойлова Р.С., Шкловский-Корди Н.Е., Гилязитдинова Е.А., Губкин А.В., Джулакян У.Л., Марголин О.В., Марьин Д.С., Чернова Н.Г., Кравченко С.К. Структура T/NK-клеточных лимфатических опухолей в Гематологическом научном центре РАМН. Проблемы гематологии и переливания крови. 2005; (4): 30-4.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Виноградова Ю.Е., Зингерман Б.В. Нозологические формы и выживаемость пациентов с Т- и НК-клеточными лимфатическими опухолями, наблюдавшихся в ГНЦ в течение 10 лет. Клиническая онкогематология. Фундаментальные исследования и клиническая практика. 2011; 4(3): 201-12.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Frizzera G, Moran E.M, Rappaport H. Angioimmunoblastic lymphadenopathy with dysproteinaemia. Lancet. 1974; 1:1070-3.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Lukes R.J, Tindle B.H. Immunoblastic lymphadenopathy. A hyperimmune entity resembling Hodgkin's disease. N Engl J Med. 1975 Jan 2; 292(1):1-8.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Frizzera G, Moran E.M, Rappaport H. Angioimmunoblastic lymphadenopathy: diagnosis and clinical course. Am J Med. 1975; 59: 803-18.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Dogan A, Attygalle A.D, Kyriakou C. Angioimunoblastic T-cell lymphoma. Br J Haematol. 2003; 121:681-91.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Willenbrock K, Renné C, Gaulard P, Hansmann M.L. In angioimmunoblastic T-cell lymphoma, neoplastic T cells may be a minor cell population. A molecular single - cell and immunohistochemical study. Virchows Arch. 2005 (Jan); 446(1):15-20.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>De Leval L, Christian Gisselbrecht C, Gaulard P. Advances in the understanding and management of angioimmunoblastic T-cell lymphoma. Br J Haematol. 2009; 148: 673-89. doi:10.1111/j.1365-2141.2009.08003.x</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Aizawa Y, Zawadzki Z.A, Micolonghi T.S, Mc Dowell J.W, Neiman R.S. Vasculitis and Sjögren's syndrome with IgA-IgG cryoglobulinemia terminating in immunoblastic sarcoma. Am J Med. 1979 Jul; 67(1):160-6.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Lin P, Hao S, Handy B.C, Bueso-Ramos C.E, Medeiros L.J. Lymphoid neoplasms associated with IgM paraprotein: a study of 382 patients. Am J Clin Pathol. 2005 (Feb);123(2):200-5.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Cartron G, Roingeard P, Benboubker L, Vaillant L, Tartas S, Delain M, Lefranc T, Brémond J.L, Bout M, Linassier C, Colombat P. Sezary syndrome in a patient with multiple myeloma: demonstration of a clonally distinct second malignancy. Eur J Haematol. 1999 (Nov); 63(5):354-7.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Bryant E, Ronan S.G, Iossifides I.A. Plasma cell myeloma in a patient with a cutaneous T-cell lymphoma. Cancer. 1982 Nov 15; 50(10): 2122-5.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Kyle R.A, Durie B.G, Rajkumar S.V, Landgren O, Blade J, Merlini G, Kroger N, Einsele H, Vesole D.H, Dimopoulos M, San Miguel J, Avet-Loiseau H, Hajek R, Chen W.M, Anderson K.C, Ludwig H, Sonneveld P, Pavlovsky S, Palumbo A, Richardson P.G, B Barlogie B, Greipp P, Vescio R, Turesson I, Westin J, Boccadoro M. Monoclonal gammopathy of undetermined signiﬁcance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia. 2010; 24(6):1121-7. doi:10.1038/leu.2010.60</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Dispenzieri A, Katzmann J.A, Kyle R.A, Larson D.R, Melton L.J 3rd, Colby C.L, Therneau T.M, Clark R, Kumar S.K, Bradwell A, Fonseca R, Jelinek D.F, Rajkumar S.V. Prevalence and risk of progression of light - chain monoclonal gammopathy of undetermined significance: a retrospective population - based cohort study. Lancet. 2010 (May 15); 375(9727):1721-8. doi: 10.1016/S0140-6736(10)60482-5</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Чернова Н.Г., Виноградова Ю.Е., Сидорова Ю.В., Капланская И.Б., Гилязитдинова Е.А., Горенкова Л.Г., Марьин Д.С., Кременецкая А.М., Воробьев А.И., Кравченко С.К. Длительные режимы цитостатической терапии ангиоиммунобластной Т-клеточной лимфомы. Клиническая онкогематология. Фундаментальные исследования и клиническая практика. 2014; 7(1):57-62.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Papadi B, Polski J.M, Clarkson D.R, Liu-Dumlao T.O. Atypical angioimmunoblastic T-cell lymphomas masquerading as systemic polyclonal B-immunoblastic proliferation. Virchows Arch. 2012; 461:323-31. doi: 10.1007/s00428-012-1280-5</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Nagoshi H, Kuroda J, Kobayashi T, Maegawa S, Chinen Y, Kiyota M, Nakayama R, Mizutani S, Shimura Y, Yamamoto-Sugitani M, Matsumoto Y, Horiike S, Taniwaki M. Clinical manifestation of angioimmunoblastic T-cell lymphoma with exuberant plasmacytosis. Int J Hematol. 2013 Sep; 98(3):366-74. doi: 10.1007/s12185-013-1411-z</mixed-citation></ref></ref-list></back></article>
